Immunocidin® Equine Now Available in 5mL Format for U.S. and Canadian Veterinarians

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Belleville, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia

NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.

learn more

Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians

An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).

learn more

NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves

NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.

learn more

Follow NovaVive on Social Media.